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ABSTRACT Antimalarial interventions have yielded a signiﬁcant decline in malaria
prevalence in The Gambia, where artemether-lumefantrine (AL) has been used as a
ﬁrst-line antimalarial for a decade. Clinical Plasmodium falciparum isolates collected
from 2012 to 2015 were analyzed ex vivo for antimalarial susceptibility and geno-
typed for drug resistance markers (pfcrt K76T, pfmdr1 codons 86, 184, and 1246, and
pfk13) and microsatellite variation. Additionally, allele frequencies of single nucleo-
tide polymorphisms (SNPs) from other drug resistance-associated genes were com-
pared from genomic sequence data sets from 2008 (n  79) and 2014 (n  168). No
artemisinin resistance-associated pfk13 mutation was found, and only 4% of the iso-
lates tested in 2015 showed signiﬁcant growth after exposure to dihydroartemisinin.
Conversely, the 50% inhibitory concentrations (IC50s) of amodiaquine and lumefan-
trine increased within this period. pfcrt 76T and pfmdr1 184F mutants remained at a
prevalence above 80%. pfcrt 76T was positively associated with higher IC50s to chlo-
roquine. pfmdr1 NYD increased in frequency between 2012 and 2015 due to lume-
fantrine selection. The TNYD (pfcrt 76T and pfmdr1 NYD wild-type haplotype) also in-
creased in frequency following AL implementation in 2008. These results suggest
selection for pfcrt and pfmdr1 genotypes that enable tolerance to lumefantrine. In-
creased tolerance to lumefantrine calls for sustained chemotherapeutic monitoring
in The Gambia to minimize complete artemisinin combination therapy (ACT) failure
in the future.
KEYWORDS alleles, antimalarial agents, artemisinin combination therapies, drug
resistance evolution, ex vivo susceptibility, haplotypes, malaria elimination
There are increasing reports on the persistence of Plasmodium falciparum para-sitemia and elevated rates of reinfection following artemisinin combination thera-
pies (ACTs) (1–5). These suggest that the therapeutic efﬁcacy of ACTs might have been
compromised beyond Southeast Asia, where artemisinin resistance has been conﬁrmed
(6, 7). Global vigilance against artemisinin resistance is therefore vital for sustaining
successes toward malaria elimination, particularly in Africa, where malaria is still a
signiﬁcant health problem (7). Approaches to the routine surveillance of antimalarial
therapeutic efﬁcacy include ex vivo and molecular testing of P. falciparum isolates from
natural populations (8). These assays determine the susceptibility of individual infec-
tions to several antimalarial drugs without the interference of human factors, such as
dosing, compliance, immunity, and metabolism. Most P. falciparum ex vivo susceptibil-
ity assays report the concentration of antimalarial drugs that reduce parasite growth by
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half (50% inhibitory concentration [IC50]). Recently, the ring-stage survival assay (RSA)
was developed to assess parasites’ susceptibility to artemisinin (9, 10). With increased
drug pressure from elimination interventions, they provide early indications of drug
tolerance or developing resistance in parasite populations. Besides phenotypic assays,
molecular surveys of drug resistance-associated genetic polymorphisms can be imple-
mented in longitudinal samples of populations to monitor trends in mutant allele
frequencies.
Mutations in the P. falciparum multidrug resistance (pfmdr1), chloroquine resistance
transporter (pfcrt), dihydrofolate reductase (pfdhfr), and dihydropteroate synthase
(pfdhps) genes have been widely described (11, 12). However, many mutations in other
gene loci have been associated with drug resistance (13–16), including genes for
multidrug resistance-associated proteins (pfmrp1 and pfmrp2), calcium-transporting
ATPase (pfatp6), multidrug resistance protein 2 (heavy metal transport family) (pfmdr2),
plasmepsin III, histo-aspartic protease (pfhap), sodium/hydrogen exchanger H anti-
porter (pfnhe), ubiquitin carboxyl-terminal hydrolase 1, putative (pfubp1), and Kelch
propeller proteins (pfk13) (17). The pfk13 gene is particularly important because single
nucleotide polymorphisms (SNPs) on its propeller domain have been strongly associ-
ated with artemisinin resistance in Southeast Asia (18). It is not clear how the preva-
lences of these mutations have been affected by the substantial reduction in malaria
transmission and sustained drug pressure in countries in sub-Saharan Africa, such as
The Gambia (19–21).
The Gambia has achieved a substantial reduction in the malaria burden over the last
15 years, due to the high coverage of long-lasting insecticidal nets and prompt
diagnosis and treatment with artemether-lumefantrine (AL) as a ﬁrst-line ACT (19, 22).
AL is procured centrally with support from the Global Fund and distributed to all public
health facilities. However, AL, other ACTs, and antimalarials, such as chloroquine (CQ)
and sulfadoxine-pyrimethamine (SP), are available from private pharmacies and the
informal health sector. When AL was introduced in 2008, mutations related to SP
resistance were almost at ﬁxation, while the prevalence of mutations against quino-
lines, namely, pfcrt K76T and pfmdr1 N86Y, were 60% and 30%, respectively (23).
Though ACTs remain highly efﬁcacious, high frequencies of nonsynonymous mutations
on the K13 gene have been reported (24). In neighboring Senegal, other K13 mutations
have emerged, and there has been an increase in the frequency of pfmdr1 Y184F
mutants associated with reduced sensitivity to artemisinin (25–27). With these reports
and the lack of a readily deployable alternative to ACTs, continuous surveillance of
polymorphisms and ex vivo testing in The Gambia and across the subregion are needed
to detect trends that could further compromise ACT efﬁcacy.
To determine the changes in the prevalences of drug resistance markers and their
effect on antimalarial tolerance, we analyzed the ex vivo drug susceptibility phenotypes
of P. falciparum isolates from western Gambia collected over four transmission seasons
(2012 to 2015). The temporal patterns of drug resistance alleles and haplotypes were
determined in these populations and from genomes of isolates collected in 2008 and
2014. Our results show that antimalarial drug resistance mutations remain at signiﬁcant
frequencies, while ex vivo susceptibilities to ACT partner drugs, lumefantrine (LUM) and
amodiaquine (AMD), decreased over the period.
RESULTS
Drug susceptibility. We found SYBR Green-based ﬂuorimetry or ﬂow cytometry in
combination with curve-ﬁtting in IVART (28) to be reliable in estimating IC50s (see Table
S1 and Fig. S1 in the supplemental material). With this approach, we successfully
conducted 1,238 ex vivo antimalarial drug susceptibility (IC50) assays of P. falciparum by
ﬂuorimetry from 2012 to 2015 (Table 1). In malaria samples from 2013 to 2015, we
consistently tested parasite isolates recruited during therapeutic efﬁcacy studies
against AMD, LUM, artemether (ARM), and dihydroartemisinin (DHA). We found signif-
icantly increasing IC50s for isolates from consecutive years against AMD (P  0.0082)
and LUM (P  0.0001) (Fig. 1a and b and Table S2). Over the same period, there was a
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3-fold decrease in the IC50s to the artemisinin derivatives ARM (P  0.0001) and DHA
(P  0.0001) (Fig. 1c and d). The geometric mean of the IC50s between isolates from
pairs of years was signiﬁcantly different between successive years for all four drugs
except for AMD, which was signiﬁcant only between 2013 and 2015 (Table S3). There
was a signiﬁcant positive correlation in the IC50s to DHA and ARM (P  0.0001) (Table
2). In contrast, there was a negative correlation between ARM and LUM IC50s (P 
0.00471). LUM IC50s were also negatively correlated with DHA, although not signiﬁ-
cantly (P  0.2686). For isolates assayed in 2012, 2013, and 2014, the IC50s for
meﬂoquine (MQ) did not change signiﬁcantly (P  0.3035) (Fig. S2a). However, the
percentage of isolates with an IC50 beyond the 30 nM resistance threshold decreased
from 71% to 54%.
Prevalence of isolates above resistance threshold. To determine the prevalence
of potentially resistant isolates in 2015, we analyzed 46 isolates for antimalarial sus-
ceptibility using a sensitive ﬂow cytometry technique. We included CQ, quinine (QN),
sulfadoxine (SD), and pyrimethamine (PYR) in our drug panel. Based on published ex
vivo resistance thresholds, 43% of the isolates were resistant to CQ, 0% to QN, 15% to
LUM, and 11% to AMD (Fig. 2a). Eighteen percent and 87% of the isolates had SD and
PYR IC50s above 1 M, respectively (Fig. 2b). Only one isolate had an IC50 above cutoff
for the ART derivatives DHA and ARM (Fig. 2c). At a resistance threshold of 100 nM, the
proportion of resistant isolates against CQ increased from 33% in 2012 to 43% in 2015,
although there was no signiﬁcant difference between the two populations (geometric
means, 63.50 nM to 66.02 nM) (Fig. S2b).
Ring survival of 2015 parasites. Successful growth rates and percent survival of
staggering-stage parasites following DHA exposure were achieved for 50 (73.5%) out of
68 isolates assayed by RSA in 2015. Parasite growth was found in 13 isolates (26%) after
DHA exposure (Fig. 2d). The survival rate for isolates ranged from 0.05 to 2.5%. Only two
(4%) isolates had a survival rate greater than 1%. There was a negative correlation
between percent ring survival and the IC50s of LUM (P 0.039, r2 0.196) and QN (P
0.035, r2 0.186) (Fig. 3a and b). Conversely, a higher survival rate was seen for parasite
isolates with higher IC50s against SD (P  0.0038, r2  0.438) (Fig. 3c). There was also
a positive correlation between survival rate and ARM IC50, but this was not signiﬁcant
(P  0.565, r2  0.016) (Fig. 3d).
Prevalence of drug resistance alleles. Trends in pfmdr1 and pfcrt drug resistance
mutation frequencies were not consistent but ﬂuctuated between years, with a rise in
frequencies of pfmdr1 86Y and 1246Y mutants in 2013 and 2015 when there was a
decline in pfcrt 76T and pfmdr1 184F compared to previous years (Fig. 4a). The mutant
pfmdr1 86Y variant was present in 10% of the infections analyzed from 2012 to 2015
TABLE 1 Number of clinical Plasmodium falciparum isolates recruited from Brikama, The
Gambia, between 2012 and 2015 and assayed for ex vivo drug susceptibility or
genotyped for microsatellite diversity and drug resistance-associated SNPs in pfmdr1,
pfcrt, pfatpase6, and pfk13
Drug or genotyping 2012 2013 2014 2015 Total
Drugs
Lumefantrine 33 65 33 78 209
Amodiaquine 45 33 100 178
Dihydroartemisinin 63 35 96 194
Artemether 76 28 96 200
Meﬂoquine 38 32 39 109
Artemisinin 46 34 80
Chloroquine 45 46 91
Quinine 59 59
Sulfadoxine 59 59
Pyrimethamine 59 59
Genotyping
SNPs 78 125 67 101 371
Microsatellites 56 59 69 184
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but showed a net increase within this period, although this was not statistically
signiﬁcant (P  0.47152). Mutant pfmdr1 1246Y alleles were found in 1% of the
isolates across years except for 2013, when they were present in 3% of the isolates. At
least 70% of the isolates carried the pfmdr1 184F and pfcrt 76T mutant variants. There
was a small insigniﬁcant decrease in the prevalence of infections with these variants
(pfmdr1 184F and pfcrt 76T) in 2015 compared to 2012 (P  0.13622 and 0.34212,
FIG 1 In vitro drug susceptibilities of Plasmodium falciparum isolates collected from Brikama (western Gambia) during the
transmission seasons from years 2013 to 2015. Each plot shows the log10 of the 50% inhibitory concentration (logIC50) of
isolates for a drug grouped per year of isolate collection as labeled on the x axes. Each point is the logIC50 for an isolate
against amodiaquine (AMD) (a), lumefantrine (LUM) (b), dihydroartemisinin (DHA) (c), and artemether (ARM) (d). The
median for each drug per year is shown as broken red lines. Lines connect pairs of years for which the distribution of IC50s
were signiﬁcantly different at a P value of 0.05 (*). The most signiﬁcant differences had P values of 0.0001 (****).
TABLE 2 Correlation between the IC50s against AMD, LUM, ARM, and DHA for clinical
P. falciparum isolates analyzed between 2013 and 2015
Drug pair r r2 P valuea 95% CI
AMD-LUM 0.078 0.0060 0.3668 0.091 to 0.24
AMD-DHA 0.0076 5.817e-005 0.9277 0.15 to 0.17
AMD-ARM 0.099 0.0098 0.2306 0.063 to 0.26
ARM-LUM 0.172 0.0295 0.00471 0.33 to 0.0023
ARM-DHA 0.633 0.4007 <0.0001 0.528 to 0.718
LUM-DHA 0.095 0.009 0.2686 0.26 to 0.074
aValues in bold are signiﬁcant P values for pairwise comparisons.
Amambua-Ngwa et al. Antimicrobial Agents and Chemotherapy
December 2017 Volume 61 Issue 12 e00759-17 aac.asm.org 4
 o
n
 N
ovem
ber 14, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
respectively). The prevalence of the 76T mutant allele was lowest (82%) in 2013. No
isolates were found with mutant alleles at the four pfK13 codons (Y493H, R539T, I543T,
and C580Y) associated with the artemisinin delayed clearance phenotype. Prior to the
publication of the pfK13-associated mutations, we had genotyped L402V of pfatpase6,
and this showed a 3-fold increase in prevalence from 2012 to 2014 (2.94 to 7.45%).
The most common haplotype for the four codons in pfcrt and pfmdr1 combined was
TNFD, incorporating mutant alleles at pfcrt codon 76 and pfmdr1 codon 184. Its
frequency ﬂuctuated between years, but it remained at above 50% in 2015. For the
years that there was an increase in the prevalence of TYFD, KNYD, and mixed haplo-
types, there was a decline in the frequency of the highly prevalent TNFD, TNYD, and
KNFD variant haplotypes (Fig. 4b). No triple pfmdr1 mutants were found at codon 86,
184, or 1246. The frequency of the NFD haplotype of pfmdr1, which has a mutant
FIG 2 In vitro drug susceptibilities of Plasmodium falciparum isolates collected in the year 2015 from Brikama determined by
ﬂow cytometry (ACCURI) and IVART for standard inhibitory drug concentrations (IC50) and RSA against dihydroartemisinin. The
logIC50 for each isolate is shown for quinolines (chloroquine [CQ], quinine [QN], AMD, and LUM) (a), SP drugs sulfadoxine (SD)
and pyrimethamine (PYR) (b), and artemisinin derivatives DHA and ARM (c). (d) RSA. The percentage of infected cells with
parasite growth after DHA treatment of ring stages for each isolate is shown. Broken red lines are the median value of the
isolates for each assay.
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variant only at codon 184, ﬂuctuated between alternate years, with a net decline of 13%
between 2012 and 2015 (Fig. 4c). The wild-type haplotype (NYD) gained a net increase
in prevalence of 11% between 2012 and 2015, but this was not signiﬁcant (Fig. S3). The
most prevalent two-locus haplotype of pfmdr1 was ND at codons 86 and 1246, present
in at least 80% of the isolates genotyped across years (Fig. 4d). This was followed by NF
(codons 86 and 184) and FD (codons 184 and 1246). The prevalence of these 3
haplotypes increased or declined in alternate years, but there was a net decline of 11%
in prevalence between 2012 and 2015. The wild-type NY haplotype (codons 86 and
184) increased by 10% within the same period. The double mutant (YF) for pfmdr1
codons 86 and 184 was present at 4% in 2012, and this increased to 6% in 2015. Other
double-mutant combinations of the three codons were present only transiently and
below 2%. Chi square and permutation tests of the differences in proportions of these
haplotype variants between years were insigniﬁcant.
There was a signiﬁcant increase in IC50s to CQ for isolates that had the 76T mutation
at the pfcrt codon 76 (P  0.000, Fig. 5a). Lower IC50s were observed for 76T mutants
against QN, AMQ, and LUM, although these were nonsigniﬁcant. There was a wide
range of IC50s for isolates with either the mutant (NFD) or wild (NYD) pfmdr1 haplotype
against all drugs (Fig. 5b). Compared to NYD, the IC50s of isolates with the NFD
haplotype were nonsigniﬁcantly higher against QN and LUM but lower against CQ and
AMD. There was no signiﬁcant association between the pfcrt or pfmdr1 haplotypes and
the IC50s for ART derivatives.
Frequencies of drug resistance loci from genomes of 2008 and 2014 isolates.
The allele frequencies of SNPs in drug resistance-associated genes determined from
publicly available genomes sequences of P. falciparum isolates collected from The
Gambia in 2008 and 2014 were generally below 5% in both populations. However,
18 polymorphisms showed an increase in nonreference allele frequencies in 2014
FIG 3 Correlation between drug IC50s (y axes) for LUM (a), QN (b), SD (c), and ARM (d) and the percentage
of rings surviving after dihydroartemisinin exposure. Each point corresponds to the IC50 plotted against the
percentage of infected cells with parasite growth for an isolate, with the conﬁdence interval of the IC50
shown as bars.
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isolates compared to 2008 isolates (Table S4). These included 2 polymorphisms
in ABC transporters (pfmrp2), 5 polymorphisms in calcium-transporting ATPase
(pfatp6), 1 polymorphism in multidrug resistance protein (pfmdr1), 2 polymorphisms in
multidrug resistance protein 2 (heavy metal transport family) (pfmdr2), 2 polymor-
phisms in multidrug resistance-associated protein 1 (pfmrp1), 1 polymorphism in
plasmepsin III, histo-aspartic protease (pfhap), 5 polymorphisms in sodium/hydrogen
exchanger, Na, H antiporter (pfnhe), and 3 polymorphisms in ubiquitin carboxyl-
terminal hydrolase 1, putative (pfubp1). These allele frequency shifts were small, and
only ﬁve of the analyzed SNPs attained a frequency of 5% or higher in the 2014
population: pfatpase6 N569K (0.073 to 0.08), pfmrp2 A1643V (0.01 to 0.05), and pfnhe
H1401Q (0.03 to 0.05). pfnhe I1480K and S207F mutations were not detected in the
2008 population but were present at 5% and 10%, respectively, of the isolates from
2014.
Parasite population structure. The level of microsatellite heterozygosity was
similar across all populations (2013 to 2013), with a mean of 0.813 (standard deviation,
0.049; 95% conﬁdence interval [CI], 0.714 to 0.885). The genetic distances between the
three yearly populations determined by Weir and Cockerham’s index of differentiation
(Fst) were insigniﬁcant between all population pairs (Table S6). The three populations
FIG 4 Temporal trends in the frequencies of Plasmodium falciparum drug resistance alleles at chloroquine resistance transporter (pfcrt), multidrug
resistance protein 1 (pfmdr1), and calcium-transporting ATPase (pfatpase6) (a), pfcrt-pfmdr1 haplotypes (b), pfmdr1 codons 86-184-1246
haplotypes (c), and biallelic haplotypes at pfmdr1 codons 86, 184, and 1246 (d). Isolates were collected across four transmission seasons (years
2012 to 2015) from Brikama, The Gambia. Each point represents the frequency (y axes) plotted against the year (x axes) isolates were collected.
Each line shows the trend for frequencies of alleles or haplotypes in the ﬁgure legends.
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showed no clustering by year of sampling based on the alleles of the six microsatellite
loci genotyped. However, there were three subclusters determined by both axes 1 and
2 of principal components, with memberships constituting isolates from all three time
points (Fig. S4).
DISCUSSION
Using clinical Plasmodium falciparum isolates collected through three transmission
seasons (2013 to 2015), we found increasing ex vivo tolerance to ACT partner drugs
FIG 5 In vitro sensitivity (IC50) of Plasmodium falciparum isolates collected in the year 2015 for mutant or
wild-type alleles at pfcrt K76T codon (a) and pfmdr1-86-184-1246 haplotypes of isolates assayed against
quinolines (CQ, QN, LUM, and AMD) and artemisinin derivatives (DHA and ARM) (b). Each point in a group
represents the logIC50 for an isolate with the speciﬁc allele or haplotype and drug labeled on the x axes.
Broken red lines show the median logIC50 values for each haplotype group per drug.
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(LUM and AMD) and a high prevalence of known drug resistance alleles in pfmdr1 and
pfcrt 6 years after the introduction of AL in The Gambia (West Africa). Such a longitu-
dinal analysis serves to provide an early warning on any compromise in the efﬁcacy of
ACTs. Our results are particularly relevant for countries, such as The Gambia, where
ACTs have been in use for a decade, and the last ex vivo drug susceptibility testing of
P. falciparum in this population was done 17 years ago, prior to their ofﬁcial introduc-
tion (29). Moreover, The Gambia is bordered on three sides by Senegal, which uses a
different ACT artesunate-amodiaquine (ASAQ), and has reported increasing ex vivo
tolerance to AMD (30). Amodiaquine is not ofﬁcially recommended for the treatment of
malaria in The Gambia, but human population movement between these countries
could facilitate an exchange of drug-resistant parasites. Our results are also in line with
reports from other West African countries of sustained ex vivo resistance of local P.
falciparum populations to multiple quinolines that are not ofﬁcially in use (31). While
this could partly be due to cross-resistance between quinolines, such as CQ and AMD,
access to these drugs from the informal/private sector could be selecting for less-
susceptible parasites (32). Indeed, the IC50s for CQ determined in 2013 and 2015 in The
Gambia remained high above the resistance cutoff despite a 2-fold reduction in median
values within this period. For 39 isolates assayed in 2014, MQ resistance was still at 54%
but down from 71% in the previous year. These results suggest closer monitoring of
quinolines, as sustained drug pressure and multidrug-resistant P. falciparum could limit
options for ACTs that can be ofﬁcially deployed (33).
Lumefantrine in combination with ARM is the most widely used ACT in The Gambia
and most of sub-Saharan Africa. While AL remains highly efﬁcacious in The Gambia, an
increasing proportion of patients with parasitemia between the 3rd and 28th days after
treatment have been observed (Gambian antimalarial therapeutic efﬁcacy studies in
2012 to 2014, our unpublished data). This is consistent with our ﬁnding of increasing
IC50s to LUM in the same period. Lumefantrine resistance is a major threat to the
efﬁcacy of AL-based ACT, since evidence of rapid selection against it was reported in
isolates with no prior exposure to ACTs (34). The parasite populations analyzed here
showed no genetic differentiation but sustained susceptibility to the artemisinin de-
rivatives ARM and DHA. This sustained susceptibility was conﬁrmed by the results of an
RSA conducted for the 2015 samples, which showed only 2 out of 50 isolates as having
a greater than 1% survival rate after DHA exposure. Interestingly, we observed an
increased survival rate against DHA for isolates with higher SD IC50s. Folate pathways
are important for cell survival, and hence, we hypothesize that isolates that could
salvage folates in the presence of SD could survive better against DHA. This ﬁnding will
require further investigation, especially as selective pressure from the use of SP in
season malaria chemoprophylaxis (SMC) could encourage DHA tolerance. However, we
found none of the pfK13 polymorphisms associated with artemisinin resistance in the
four populations genotyped. These results together support the continuous use of AL
in The Gambia, without excluding future considerations for a change in ACT regimen
if LUM tolerance increases.
The choice of ACT alternatives could be guided by the prevalence of polymorphisms
associated with antimalarial drug resistance in the population. We showed here that
the major CQ resistance mutation pfcrt 76T remained highly prevalent in current
isolates from The Gambia. Its slow temporal decline contrasts with reports in Kenya and
Malawi, where the dramatic return of the sensitive genotype sparked reconsideration of
CQ for malaria treatment (35, 36). We also found high frequencies of 86N and 10% of
isolates with 1246D, which lead to higher in vitro and in vivo tolerance and reinfection
rates after AL treatment (37). These were linked in the dominant 86N/184F/1246D
pfmdr1 haplotype found in isolates with higher IC50s to LUM. This haplotype had been
shown to resist 15-fold the serum concentration of clinical doses of LUM (38). AL also
selects for other pfmdr1 haplotypes, like the NYD, which showed a steady increase in
frequencies between temporal populations (39). This is consistent with studies in West
Africa that found selection of these haplotypes by AL (40–42). Considering the risk to
AL efﬁcacy, an extended study of the temporal trends and association of these alleles
Evolution of Antimalarial Resistance in The Gambia Antimicrobial Agents and Chemotherapy
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with drug efﬁcacy as parasite prevalence reduces could guide policy on ACTs in The
Gambia. Taking advantage of publicly available genomic data sets from 2008 and 2014,
we found increased frequencies of SNPs in a number of drug resistance-associated
genes, suggesting a need for sustained vigilance as drug interventions continue.
Sustained pressure from quinolines are maintaining pfcrt resistance variants. Hence, the
widely proposed ACT regiments, such as DHA-piperaquine, will not be a good option,
as piperaquine selects for CQ-resistant parasites.
The parasite population studied here has been in a decline for over a decade, and
we prognosed that inbreeding could favor the rapid establishment of introduced or
emerging drug-tolerant strains. The temporal populations showed no substructuring,
as expected across Africa. The levels of heterozygosity at neutral microsatellite loci were
comparable across the temporal populations and to those in previous reports (43). This
high heterogeneity and lack of structure should disfavor easy establishment of new
drug resistance mutants, as recombination remains signiﬁcant.
This study combines molecular and phenotypic analyses to provide an insight into
drug susceptibility trends and possible mechanisms determining patterns of suscepti-
bility as ACTs continue to be widely implemented in The Gambia. It has shown
artemisinin derivatives to be continuously potent against P. falciparum isolates from
West of The Gambia. There is, however, an increase in ex vivo tolerance to the ACT
partner drug lumefantrine. Levels of the pfmdr1 184F and pfcrt 76T mutants remain
high, while there are emerging mutations in pfmrp2 and pfnhe that suggest continuous
selection from quinoline-based antimalarials. These results call for continuous and
rigorous surveillance to sustain the useful life span of currently employed ACTs in The
Gambia and other regions endemic for malaria.
MATERIALS AND METHODS
Consent and sample collection. The study design and protocols were approved by the Gambian
Government/MRC Joint Ethics Committee. Study subjects (age 6 months to 15 years) were recruited from
the Brikama Health Centre, located in western Gambia, as part of therapeutic efﬁcacy studies conducted
during the 2012-2015 rainy (transmission) seasons (September to December). Inclusion criteria were a
history of fever in the preceding 24 h, P. falciparum monoinfection at a parasite density of 1,000/l of
blood, as determined by microscopy, and no symptoms of complicated/severe malaria. Caregivers
provided a written informed consent after the procedures were explained, and children between 12 and
15 years provided an assent in addition. A 2.5-ml blood sample was collected into EDTA tubes (BD
Biosciences, Germany) and transported on ice (4°C) within 4 h of collection to the MRC, The Gambia
(MRCG) laboratories for analysis. Following centrifugation, plasma and the buffy coat were recovered and
stored frozen. RPMI 1640 medium (Sigma-Aldrich, UK) was added to the remaining cell pellet to obtain
a 50% cell suspension, which was then overlaid on 3 ml of NycoPrep for leukocyte depletion (Axis Shield,
UK). Leukocytes (peripheral blood mononuclear cells [PBMCs]) were separated following centrifugation
at 2,500 rpm for 10 min with no break. The red blood cell (RBC) pellet was washed three times with RPMI
1640 medium and resuspended in growth medium at 2% hematocrit for drug susceptibility assays.
Ex vivo drug susceptibility assays. Laboratory-maintained P. falciparum strains (3D7, DD2, HB3, K1,
and W2) were ﬁrst assayed against lumefantrine (LUM), dihydroartemisinin (DHA), artemisinin (ART), and
artesunate (ARS) to compare the consistencies of ﬂuorimetric and cytometric determinations of parasite
growth. We compared ﬁtted curves between methods using GraphPad Prism and IVART. Isolates from
2013 to 2015 were then tested in triplicate on a panel of drugs composing ACTs, i.e., LUM, DHA,
artemether (ARM), and amodiaquine (AMD), donated by the Worldwide Anti-Malarial Resistance Network
(WWARN). The following drugs with historically reported antimalarial resistance were also tested: CQ in
2012, 2013, and 2015; quinine (QN) and meﬂoquine (MQ) in 2013 and 2014; and pyrimethamine (PYR)
and sulfadoxine (SD) in 2015. The ﬁnal concentration ranges tested were 750 to 3 nM for CQ, 1,500 to
6 nM for QN, 300 to 1.2 nM for MQ, 2,000 to 8 nM for LUM, 100 to 0.4 nM for AMD, 150 to 0.6 nM for
ARM and DHA, 2,600 to 10 nM for SD, and 295,000 to 3 nM for PYR. Samples or control isolates (P.
falciparum 3D7, DD2, and W2) were tested at a parasitemia of 0.5 to 1% in 2% hematocrit. Smears of the
drug-free wells were observed by microscopy at the end of this period to ensure that the parasite strains
had grown through a full cycle. For SYBR Green staining of parasite DNA, the cell pellet of each assay was
suspended in 100 l of SYBR Green I (1:10,000 dilutions in phosphate-buffered saline [PBS]) (Invitrogen,
USA) and incubated in the dark for 1 h. Stained cells were washed in RPMI and resuspended in 100 l
of ﬁltered PBS, and 100,000 events were acquired on an Accuri ﬂow cytometer (BD). Flow cytometry cell
counts were analyzed with the FlowJo software (Tree Star, Inc.). For ﬂuorimetric determination of
parasitemia on a Fluoroskan, 50 l of stained cells was lysed in an equal volume of SYBR Green lysis
buffer containing 0.005% SDS and read at 450 nm.
Cell counts were ﬁtted with GraphPad Prism version 6 by a nonlinear regression against the logarithm
of the drug concentration, using the formula for sigmoidal dose-response (variable slope) to yield the
dose-response curve and resultant 50% inhibitory concentration (IC50). The mean, median, and geometric
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mean of the IC50s were calculated for all populations. For validation of the IC50 results, data were also
submitted online for ﬁtting using the WWARN IVART software for all samples from each year. Agreement
between the GraphPad and IVART results was assessed using Bland-Altman analysis. Nonparametric
statistical tests in Prism and R were used to compare IC50 data between the transmission seasons.
RSA. For 2015, 68 isolates were tested against DHA by a ring-stage survival assay (RSA). For the RSA
control, the P. falciparum isolates 1241 (DHA resistant) and 1239 (DHA sensitive) were analyzed together
with the population samples. Assays for each lymphocyte-depleted infected RBC sample were set up in
duplicates at 0.5 to 1% parasitemia and 2% hematocrit, as described in published protocols (10). Parasites
were exposed for 6 h to 700 nM DHA in complete culture RPMI medium (cRPMI) and 0.1% dimethyl
sulfoxide (DMSO) as a test control. Exposure was under established culture conditions (37°C in the
presence of 5% O2, 5% CO2, and 90% N2). Following this, the RBC pellets were recovered, washed once
in incomplete RPMI, and cultured for another 66 h in drug-free culture medium. Thin blood smear slides
were prepared for each duplicate test and stained with Giemsa. Parasite survival rates were determined
using the parasitemia at 0 h (before exposure), the parasitemia of the DMSO control (NE), and
DHA-exposed tests at 72 h. The growth rate for each isolate was determined as the ratio of the
nonexposed (NE) against the initial parasitemia. For each isolate with a growth rate of 1% or higher, the
parasite percent survival was calculated as (growth in DHA/growth in NE)  100.
Microsatellite genotyping. To determine the population structure, selected SNPs and six genomic
microsatellite loci (Poly, PK2, TAA81, ARA2, G377, and TAA87) were genotyped as described in previous
studies (43). Fragment sizes were checked using GeneMapper4.1 (Life Technologies software). Further
binning and size scoring were done with GeneMarker version 1.85 (SoftGenetics) to include peaks with
a relative ﬂuorescent intensity (RFU) of 100. Multilocus alleles for each sample were normalized and
corrected using the Tandem 2 software. Genetic distances and diversity for the populations were
determined in the Microsatellite Analyzer package.
Drug resistance marker genotyping. Samples were analyzed for molecular markers of drug
resistance, including pfcrt K76T, pfmdr1 N86Y, Y184F, and D1246Y, pfatpase6 L402V and E431K, and four
K13 propeller domain polymorphisms (493, 539, 540, and 580). Nucleotide alleles at SNPs determining
these mutations were assayed by allelic discrimination using 20 TaqMan assay mixes with probes
targeting wild and mutant SNPs labeled with 6-carboxyﬂuorescein (FAM) and VIC, respectively. Primers
and probes for the four K13 SNPs were custom designed and sourced from Metabion (Table S5). DNA
from each isolate was assayed in a 15-l 1 universal TaqMan PCR master mix on the Bio-Rad CFX96
real-time thermocycler. Clustering of samples and allele scoring were achieved using the Bio-Rad CFX96
manager software. A subset of samples (10%) with wild-type and mutant alleles were subjected to
conﬁrmatory analysis by Big Dye version 3.1 sequencing on the 3130xl genetic analyzer. Allele frequen-
cies for the targets were analyzed using the Stata software. The pfcrt K76T mutation was assayed by
high-resolution melt analysis using allele-speciﬁc probes in the Roche LightCycler. Genotypes of P.
falciparum from genome sequences of isolates collected from Brikama in 2008 and 2014 were genotyped
for haplotypes of pfcrt and pfmdr1. The derived alleles of SNPs in the following drug resistance-associated
loci were also determined: ubiquitin carboxyl-terminal hydrolase 1 (PF3D7_0104300), putative multidrug
resistance-associated protein 1 (PF3D7_0112200), bifunctional dihydrofolate reductase-thymidylate syn-
thase (PF3D7_0417200), drug/metabolite transporter, putative (PF3D7_0715800), drug/metabolite trans-
porter, putative (PF3D7_0716900), hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate
synthase (PF3D7_0810800), multidrug resistance-associated protein 2 (PF3D7_1229100), sodium/hydro-
gen exchanger, Na, H antiporter (PF3D7_1303500), ferredoxin, putative (PF3D7_1318100), kelch
protein K13 (PF3D7_1343700), multidrug resistance protein 2 (PF3D7_1447900), and plasmepsin III
(PF3D7_1408100).
Statistical analyses. GraphPad Prism and R softwares were used for all statistical analyses. For
population comparison of the drug IC50s, differences between population means were compared by the
Kruskal-Wallis test. The threshold for signiﬁcant differences between years was set at 0.05 and deter-
mined by one-way analysis of variance (ANOVA). Dunn’s multiple comparison was employed to correct
for differences between population pairs. Proportions of isolates between populations with IC50s higher
than a resistance threshold with mutant alleles or haplotypes were compared using a permutation test
in R. Simple linear regression ﬁtting was used to determine the signiﬁcance of trends in allele or
haplotype frequencies.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/AAC
.00759-17.
SUPPLEMENTAL FILE 1, PDF ﬁle, 1.0 MB.
ACKNOWLEDGMENTS
The laboratory analysis here was funded by the MRC Career Development Fellow-
ship (MRC/DFID/EDCTP2) to Alfred Amambua-Ngwa.
We are thankful to the NMCP for their collaboration in enabling sample collection
within the biannual therapeutic efﬁcacy studies. We acknowledge the contributions of
Tzerhen Ho who helped with optimizing and training on the ring survival and high-
resolution melt assays.
Evolution of Antimalarial Resistance in The Gambia Antimicrobial Agents and Chemotherapy
December 2017 Volume 61 Issue 12 e00759-17 aac.asm.org 11
 o
n
 N
ovem
ber 14, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
REFERENCES
1. Greenhouse B, Slater M, Njama-Meya D, Nzarubara B, Maiteki-Sebuguzi
C, Clark TD, Staedke SG, Kamya MR, Hubbard A, Rosenthal PJ, Dorsey G.
2009. Decreasing efﬁcacy of antimalarial combination therapy in Uganda
is explained by decreasing host immunity rather than increasing drug
resistance. J Infect Dis 199:758–765. https://doi.org/10.1086/596741.
2. Conrad MD, LeClair N, Arinaitwe E, Wanzira H, Kakuru A, Bigira V,
Muhindo M, Kamya MR, Tappero JW, Greenhouse B, Dorsey G, Rosenthal
PJ. 2014. Comparative impacts over 5 years of artemisinin-based com-
bination therapies on Plasmodium falciparum polymorphisms that mod-
ulate drug sensitivity in Ugandan children. J Infect Dis 210:344–353.
https://doi.org/10.1093/infdis/jiu141.
3. Beshir KB, Sutherland CJ, Sawa P, Drakeley CJ, Okell L, Mweresa CK,
Omar SA, Shekalaghe SA, Kaur H, Ndaro A, Chilongola J, Schallig HD,
Sauerwein RW, Hallett RL, Bousema T. 2013. Residual Plasmodium
falciparum parasitemia in Kenyan children after artemisinin-
combination therapy is associated with increased transmission to
mosquitoes and parasite recurrence. J Infect Dis 208:2017–2024.
https://doi.org/10.1093/infdis/jit431.
4. Zatra R, Lekana-douki JB, Lekoulou F, Bisvigou U, Ngoungou EB, Ndouo
FS. 2012. In vitro antimalarial susceptibility and molecular markers of
drug resistance in Franceville, Gabon. BMC Infect Dis 12:307. https://doi
.org/10.1186/1471-2334-12-307.
5. WWARN Artemisinin-based Combination Therapy (ACT) Africa Baseline
Study Group, Dahal P, d’Alessandro U, Dorsey G, Guerin PJ, Nsanzabana
C, Price RN, Sibley CH, Stepniewska K, Talisuna AO. 2015. Clinical deter-
minants of early parasitological response to ACTs in African patients
with uncomplicated falciparum malaria: a literature review and meta-
analysis of individual patient data. BMC Med 13:212. https://doi.org/10
.1186/s12916-015-0445-x.
6. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey
F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M,
Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day
NP, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resistance in
Plasmodium falciparum malaria. N Engl J Med 361:455–467. https://doi
.org/10.1056/NEJMoa0808859.
7. Snow RW. 2015. Global malaria eradication and the importance of
Plasmodium falciparum epidemiology in Africa. BMC Med 13:23. https://
doi.org/10.1186/s12916-014-0254-7.
8. Vestergaard LS, Ringwald P. 2007. Responding to the challenge of
antimalarial drug resistance by routine monitoring to update national
malaria treatment policies. Am J Trop Med Hyg 77:153–159.
9. Witkowski B, Amaratunga C, Khim N, Sreng S, Chim P, Kim S, Lim P,
Mao S, Sopha C, Sam B, Anderson JM, Duong S, Chuor CM, Taylor WR,
Suon S, Mercereau-Puijalon O, Fairhurst RM, Menard D. 2013. Novel
phenotypic assays for the detection of artemisinin-resistant Plasmo-
dium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-
response studies. Lancet Infect Dis 13:1043–1049. https://doi.org/10
.1016/S1473-3099(13)70252-4.
10. Kite WA, Melendez-Muniz VA, Moraes Barros RR, Wellems TE, Sa JM.
2016. Alternative methods for the Plasmodium falciparum artemisinin
ring-stage survival assay with increased simplicity and parasite stage-
speciﬁcity. Malar J 15:94. https://doi.org/10.1186/s12936-016-1148-2.
11. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT,
Ursos LM, Sidhu AB, Naude B, Deitsch KW, Su XZ, Wootton JC, Roepe PD,
Wellems TE. 2000. Mutations in the P. falciparum digestive vacuole
transmembrane protein PfCRT and evidence for their role in chloroquine
resistance. Mol Cell 6:861–871. https://doi.org/10.1016/S1097-2765(05)
00077-8.
12. Duraisingh MT, Cowman AF. 2005. Contribution of the pfmdr1 gene to
antimalarial drug-resistance. Acta Trop 94:181–190. https://doi.org/10
.1016/j.actatropica.2005.04.008.
13. Klokouzas A, Tiffert T, van Schalkwyk D, Wu CP, van Veen HW, Barrand
MA, Hladky SB. 2004. Plasmodium falciparum expresses a multidrug
resistance-associated protein. Biochem Biophys Res Commun 321:
197–201. https://doi.org/10.1016/j.bbrc.2004.06.135.
14. Ferdig MT, Cooper RA, Mu J, Deng B, Joy DA, Su XZ, Wellems TE. 2004.
Dissecting the loci of low-level quinine resistance in malaria para-
sites. Mol Microbiol 52:985–997. https://doi.org/10.1111/j.1365-2958
.2004.04035.x.
15. Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, Ekala MT,
Bouchier C, Esterre P, Fandeur T, Mercereau-Puijalon O. 2005. Resistance
of Plasmodium falciparum ﬁeld isolates to in-vitro artemether and point
mutations of the SERCA-type PfATPase6. Lancet 366:1960–1963. https://
doi.org/10.1016/S0140-6736(05)67787-2.
16. Hunt P, Afonso A, Creasey A, Culleton R, Sidhu AB, Logan J, Valderramos
SG, McNae I, Cheesman S, do Rosario V, Carter R, Fidock DA, Cravo P.
2007. Gene encoding a deubiquitinating enzyme is mutated in
artesunate- and chloroquine-resistant rodent malaria parasites. Mol Mi-
crobiol 65:27–40. https://doi.org/10.1111/j.1365-2958.2007.05753.x.
17. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, Kim
S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S,
Chuor CM, Bout DM, Menard S, Rogers WO, Genton B, Fandeur T, Miotto
O, Ringwald P, Le Bras J, Berry A, Barale JC, Fairhurst RM, Benoit-Vical F,
Mercereau-Puijalon O, Menard D. 2014. A molecular marker of
artemisinin-resistant Plasmodium falciparum malaria. Nature 505:50–55.
https://doi.org/10.1038/nature12876.
18. MalariaGEN Plasmodium falciparum Community Project. 2016. Genomic
epidemiology of artemisinin resistant malaria. eLife 5:e08714. https://doi
.org/10.7554/eLife.08714.
19. Ceesay SJ, Casals-Pascual C, Erskine J, Anya SE, Duah NO, Fulford AJ,
Sesay SS, Abubakar I, Dunyo S, Sey O, Palmer A, Fofana M, Corrah T,
Bojang KA, Whittle HC, Greenwood BM, Conway DJ. 2008. Changes in
malaria indices between 1999 and 2007 in The Gambia: a retrospective
analysis. Lancet 372:1545–1554. https://doi.org/10.1016/S0140-6736(08)
61654-2.
20. Mwesigwa J, Okebe J, Affara M, Di Tanna GL, Nwakanma D, Janha O,
Opondo K, Grietens KP, Achan J, D’Alessandro U. 2015. On-going malaria
transmission in The Gambia despite high coverage of control
interventions: a nationwide cross-sectional survey. Malar J 14:314.
https://doi.org/10.1186/s12936-015-0829-6.
21. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, Battle
KE, Moyes CL, Henry A, Eckhoff PA, Wenger EA, Briet O, Penny MA, Smith
TA, Bennett A, Yukich J, Eisele TP, Grifﬁn JT, Fergus CA, Lynch M,
Lindgren F, Cohen JM, Murray CL, Smith DL, Hay SI, Cibulskis RE, Gething
PW. 2015. The effect of malaria control on Plasmodium falciparum in
Africa between 2000 and 2015. Nature 526:207–211. https://doi.org/10
.1038/nature15535.
22. van den Hoogen LL, Grifﬁn JT, Cook J, Sepulveda N, Corran P, Conway
DJ, Milligan P, Affara M, Allen SJ, Proietti C, Ceesay SJ, Targett GA,
D’Alessandro U, Greenwood B, Riley EM, Drakeley C. 2015. Serology
describes a proﬁle of declining malaria transmission in Farafenni, The
Gambia. Malar J 14:416. https://doi.org/10.1186/s12936-015-0939-1.
23. Nwakanma DC, Duffy CW, Amambua-Ngwa A, Oriero EC, Bojang KA,
Pinder M, Drakeley CJ, Sutherland CJ, Milligan PJ, Macinnis B, Kwiat-
kowski DP, Clark TG, Greenwood BM, Conway DJ. 2014. Changes in
malaria parasite drug resistance in an endemic population over a 25-
year period with resulting genomic evidence of selection. J Infect Dis
209:1126–1135. https://doi.org/10.1093/infdis/jit618.
24. Ménard D, Khim N, Beghain J, Adegnika AA, Shaﬁul-Alam M, Amodu O,
Rahim-Awab G, Barnadas C, Berry A, Boum Y, Bustos MD, Cao J, Chen JH,
Collet L, Cui L, Thakur GD, Dieye A, Djalle D, Dorkenoo MA, Eboumbou-
Moukoko CE, Espino FE, Fandeur T, Ferreira-da-Cruz MF, Fola AA, Fuehrer
HP, Hassan AM, Herrera S, Hongvanthong B, Houze S, Ibrahim ML,
Jahirul-Karim M, Jiang L, Kano S, Ali-Khan W, Khanthavong M, Kremsner
PG, Lacerda M, Leang R, Leelawong M, Li M, Lin K, Mazarati JB, Menard
S, Morlais I, Muhindo-Mavoko H, Musset L, Na-Bangchang K, Nambozi M,
Niare K, Noedl H, et al. 2016. A worldwide map of Plasmodium falcipa-
rum K13-propeller polymorphisms. N Engl J Med 374:2453–2464. https://
doi.org/10.1056/NEJMoa1513137.
25. Boussaroque A, Fall B, Madamet M, Camara C, Benoit N, Fall M, Nakou-
lima A, Dionne P, Fall KB, Diatta B, Dieme Y, Wade B, Pradines B. 2015.
Emergence of mutations in the K13 propeller gene of Plasmodium
falciparum isolates from Dakar, Senegal, in 2013–2014. Antimicrob
Agents Chemother 60:624–627. https://doi.org/10.1128/AAC.01346-15.
26. Lo AC, Faye B, Ba el H, Cisse B, Tine R, Abiola A, Ndiaye M, Ndiaye JL,
Ndiaye D, Sokhna C, Gomis JF, Dieng Y, Faye O, Ndir O, Milligan P, Cairns
M, Hallett R, Sutherland C, Gaye O. 2013. Prevalence of molecular
markers of drug resistance in an area of seasonal malaria chemopreven-
tion in children in Senegal. Malar J 12:137. https://doi.org/10.1186/1475
-2875-12-137.
27. Van Tyne D, Dieye B, Valim C, Daniels RF, Sene PD, Lukens AK, Ndiaye M,
Bei AK, Ndiaye YD, Hamilton EJ, Ndir O, Mboup S, Volkman SK, Wirth DF,
Amambua-Ngwa et al. Antimicrobial Agents and Chemotherapy
December 2017 Volume 61 Issue 12 e00759-17 aac.asm.org 12
 o
n
 N
ovem
ber 14, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
Ndiaye D. 2013. Changes in drug sensitivity and anti-malarial drug
resistance mutations over time among Plasmodium falciparum parasites
in Senegal. Malar J 12:441. https://doi.org/10.1186/1475-2875-12-441.
28. Woodrow CJ, Dahlstrom S, Cooksey R, Flegg JA, Le Nagard H, Mentre
F, Murillo C, Menard D, Nosten F, Sriprawat K, Musset L, Quashie NB,
Lim P, Fairhurst RM, Nsobya SL, Sinou V, Noedl H, Pradines B, Johnson
JD, Guerin PJ, Sibley CH, Le Bras J. 2013. High-throughput analysis of
antimalarial susceptibility data by the WorldWide Antimalarial Resis-
tance Network (WWARN) in vitro analysis and reporting tool. Antimi-
crob Agents Chemother 57:3121–3130. https://doi.org/10.1128/AAC
.02350-12.
29. Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst DC.
1999. Inoculum effect leads to overestimation of in vitro resistance for
artemisinin derivatives and standard antimalarials: a Gambian ﬁeld study.
Parasitology 119:435–440. https://doi.org/10.1017/S0031182099004953.
30. Fall B, Madamet M, Camara C, Amalvict R, Fall M, Nakoulima A, Diatta B,
Dieme Y, Wade B, Pradines B. 2016. Plasmodium falciparum in vitro
resistance to monodesethylamodiaquine, Dakar, Senegal, 2014. Emerg
Infect Dis 22:841–845. https://doi.org/10.3201/eid2205.151321.
31. Fall B, Camara C, Fall M, Nakoulima A, Dionne P, Diatta B, Dieme Y, Wade
B, Pradines B. 2015. Plasmodium falciparum susceptibility to standard
and potential anti-malarial drugs in Dakar, Senegal, during the
2013–2014 malaria season. Malar J 14:60. https://doi.org/10.1186/s12936
-015-0589-3.
32. Olliaro P, Nevill C, LeBras J, Ringwald P, Mussano P, Garner P, Brasseur
P. 1996. Systematic review of amodiaquine treatment in uncompli-
cated malaria. Lancet 348:1196–1201. https://doi.org/10.1016/S0140
-6736(96)06217-4.
33. Leang R, Taylor WR, Bouth DM, Song L, Tarning J, Char MC, Kim S,
Witkowski B, Duru V, Domergue A, Khim N, Ringwald P, Menard D.
2015. Evidence of Plasmodium falciparum malaria multidrug resis-
tance to artemisinin and piperaquine in western Cambodia:
dihydroartemisinin-piperaquine open-label multicenter clinical as-
sessment. Antimicrob Agents Chemother 59:4719–4726. https://doi
.org/10.1128/AAC.00835-15.
34. Hastings IM, Ward SA. 2005. Coartem (artemether-lumefantrine) in
Africa: the beginning of the end? J Infect Dis 192:1303–1304; author
reply 1304–1305. https://doi.org/10.1086/432554.
35. Juliano JJ, Kwiek JJ, Cappell K, Mwapasa V, Meshnick SR. 2007. Minority-
variant pfcrt K76T mutations and chloroquine resistance, Malawi. Emerg
Infect Dis 13:872–877. https://doi.org/10.3201/eid1306.061182.
36. Kiarie WC, Wangai L, Agola E, Kimani FT, Hungu C. 2015. Chloroquine
sensitivity: diminished prevalence of chloroquine-resistant gene marker
pfcrt-76 13 years after cessation of chloroquine use in Msambweni,
Kenya. Malar J 14:328. https://doi.org/10.1186/s12936-015-0850-9.
37. Wurtz N, Fall B, Pascual A, Fall M, Baret E, Camara C, Nakoulima A, Diatta
B, Fall KB, Mbaye PS, Dieme Y, Bercion R, Wade B, Pradines B. 2014. Role
of Pfmdr1 in in vitro Plasmodium falciparum susceptibility to chloro-
quine, quinine, monodesethylamodiaquine, meﬂoquine, lumefantrine,
and dihydroartemisinin. Antimicrob Agents Chemother 58:7032–7040.
https://doi.org/10.1128/AAC.03494-14.
38. Malmberg M, Ferreira PE, Tarning J, Ursing J, Ngasala B, Bjorkman A,
Martensson A, Gil JP. 2013. Plasmodium falciparum drug resistance
phenotype as assessed by patient antimalarial drug levels and its asso-
ciation with pfmdr1 polymorphisms. J Infect Dis 207:842–847. https://
doi.org/10.1093/infdis/jis747.
39. Lobo E, de Sousa B, Rosa S, Figueiredo P, Lobo L, Pateira S, Fernandes N,
Nogueira F. 2014. Prevalence of pfmdr1 alleles associated with
artemether-lumefantrine tolerance/resistance in Maputo before and af-
ter the implementation of artemisinin-based combination therapy. Ma-
lar J 13:300. https://doi.org/10.1186/1475-2875-13-300.
40. Otienoburu SD, Maiga-Ascofare O, Schramm B, Jullien V, Jones JJ,
Zolia YM, Houze P, Ashley EA, Kiechel JR, Guerin PJ, Le Bras J, Houze
S. 2016. Selection of Plasmodium falciparum pfcrt and pfmdr1 poly-
morphisms after treatment with artesunate-amodiaquine ﬁxed dose
combination or artemether-lumefantrine in Liberia. Malar J 15:452.
https://doi.org/10.1186/s12936-016-1503-3.
41. Mbaye A, Dieye B, Ndiaye YD, Bei AK, Muna A, Deme AB, Yade MS,
Diongue K, Gaye A, Ndiaye IM, Ndiaye T, Sy M, Diallo MA, Badiane AS,
Ndiaye M, Seck MC, Sy N, Koita O, Krogstad DJ, Nwakanma D, Ndiaye D.
2016. Selection of N86F184D1246 haplotype of pfmrd1 gene by
artemether-lumefantrine drug pressure on Plasmodium falciparum pop-
ulations in Senegal. Malar J 15:433. https://doi.org/10.1186/s12936-016
-1490-4.
42. Achieng AO, Muiruri P, Ingasia LA, Opot BH, Juma DW, Yeda R, Ngalah
BS, Ogutu BR, Andagalu B, Akala HM, Kamau E. 2015. Temporal trends in
prevalence of Plasmodium falciparum molecular markers selected for by
artemether-lumefantrine treatment in pre-ACT and post-ACT parasites in
western Kenya. Int J Parasitol Drugs Drug Resist 5:92–99. https://doi.org/
10.1016/j.ijpddr.2015.05.005.
43. Mobegi VA, Loua KM, Ahouidi AD, Satoguina J, Nwakanma DC,
Amambua-Ngwa A, Conway DJ. 2012. Population genetic structure of
Plasmodium falciparum across a region of diverse endemicity in West
Africa. Malar J 11:223. https://doi.org/10.1186/1475-2875-11-223.
Evolution of Antimalarial Resistance in The Gambia Antimicrobial Agents and Chemotherapy
December 2017 Volume 61 Issue 12 e00759-17 aac.asm.org 13
 o
n
 N
ovem
ber 14, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
